ReviewJAC-antimicrobial resistance2026
The AMR footprint: an integrative indicator in the global response to antimicrobial resistance.
Review in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The draft updated Global Action Plan (GAP) on antimicrobial resistance (AMR) for 2026-2035 acknowledges persistent gaps between political commitment and measurable implementation. This Viewpoint argues that progress can be facilitated by a simple, integrative indicator capable of capturing multisectoral action while remaining sensitive to national context. We propose the AMR footprint as a unifying concept to operationalize the updated GAP. Analogous to the carbon footprint, the AMR footprint consolidates and tracks selected AMR-specific and AMR-sensitive indicators across human health, animal and agrifood systems, and the environment, relative to national baselines over time. Anchoring monitoring, evaluation and accountability frameworks around an AMR footprint would shift the global response from aspirational targets towards continuous improvement, transparent benchmarking, and sustained financing. Without such an operational lens, the next decade of AMR action risks repeating the implementation failures of the past.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.